Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.

Joao GorgulhoChristoph RoderburgFabian BeierCarsten BokemeyerTim Henrik BrümmendorfSven H LoosenTom Luedde

Published in: British journal of cancer (2024)

Pending prospective validation, sLAG3 and correlating circulating T-cell subsets can be used as a non-invasive predictive marker to predict outcome to ICI therapy to help identifying ideal ICI candidates in the future.

Keyphrases

patients undergoing
peripheral blood
copy number
genome wide
current status
stem cells
genome wide identification
bone marrow
cell therapy
transcription factor
genome wide analysis
clinical evaluation